Surgery for Glucagonoma



Surgery for Glucagonoma


Richard A. Prinz

Catherine A. Madorin





PATIENT HISTORY AND PHYSICAL FINDINGS



  • Glucagonoma is classically associated with the 4 “Ds”: dermatitis, diabetes, depression, and deep vein thrombosis.


  • The skin lesions associated with a glucagonoma are termed necrolytic migratory erythema and are pathognomonic for glucagonoma. It is a pruritic rash that occurs in the lower abdomen, lower extremities, perineum, perioral area, and feet (FIGS 1 and 2). It is seen in approximately 70% of patients and may be the initial presentation of the tumor.4


  • Glucose intolerance is often mild and insulin administration usually is not required.


  • Weight loss is often out of proportion to the amount of tumor burden and is due to the catabolic effect of excess glucagon.


  • Stomatitis, glossitis, and diarrhea are other frequent findings. Psychiatric manifestations may include depression, anxiety, and psychoses.


  • Glucagonoma creates a hypercoagulable state, and 30% of patients will experience a thromboembolic event.5


  • A thorough personal and family history should be taken, with particular interest in other endocrinopathies because glucagonomas may be associated with MEN-1. Glucagonomas may also secrete secondary hormones, which may lead to Zollinger-Ellison syndrome in up to 10% of patients. Less commonly, they may secrete vasoactive intestinal polypeptide (VIP), pancreatic polypeptide, somatostatin, or adrenocorticotropic hormone (ACTH).6






FIG 1 • Necrolytic migratory erythema of the lower extremity.




IMAGING



  • Glucagonomas are typically greater than 5 cm at time of diagnosis and are easier to localize preoperatively than most PNETs. Most glucagonomas are located in the body or tail of the pancreas. Rarely, they may be located outside the pancreas in the duodenal wall, accessory pancreatic tissue, or the kidney.


  • Triple-phase computed tomography (CT) scan is the firstline localization study. Somatostatin receptor scintigraphy (SRS) can also be used and can identify extraabdominal spread to lymph nodes and liver.


  • Endoscopic ultrasound (EUS), visceral angiography, and portal venous sampling may be required for glucagonomas that are difficult to identify, but this is very unusual.






FIG 2 • Necrolytic migratory erythema of the lower extremity.



SURGICAL MANAGEMENT



  • The goal of operative management of glucagonoma is an R0 resection including the primary tumor and all metastases. Patients who cannot undergo R0 resection benefit from tumor debulking because it can palliate symptoms due to excess glucagon by decreasing the levels of circulating hormone.


  • If the tumor is limited to the pancreas, surgical resection can completely reverse all clinical manifestations of a glucagonoma. This demands a formal pancreatic resection due to the large size of the tumors, usually a distal pancreatectomy with or without splenectomy. Pancreaticoduodenectomy is required for tumors in the head of the gland. Resection should include peripancreatic lymph node dissection. Although smaller tumors may be technically amenable to enucleation, the high malignant potential of these tumors suggests caution with this approach (FIG 3).


  • All nodal and hepatic metastases that can be safely removed should be excised. Hepatic metastases may be managed by either wedge resection or formal hepatic resection.


  • Tumor debulking leads to a dramatic improvement in symptoms and the hormonal manifestations of glucagonoma may be diminished for years. Repeat debulking of recurrent disease may also prolong survival.


  • In patients with MEN-1, consideration must be given to the presence of other functional and nonfunctional PNETs. If hyperparathyroidism is present as a component of the MEN-1 syndrome, it should be treated before addressing the pancreatic tumor to avoid problems with postoperative hypercalcemia.


Preoperative Planning



  • Preoperative management is focused on treating the metabolic effects of excess glucagon and preventing or treating venous thromboembolism.


  • Somatostatin analogue therapy with octreotide is titrated to symptomatic improvement. Total parenteral nutrition (TPN) may be needed if marked cachexia is present and may also help ameliorate necrolytic migratory erythema.


  • Hyperglycemia and diabetes, when present, should be controlled.


  • Patients should receive anticoagulation with Coumadin or low-molecular-weight heparin at the time of diagnosis. Preoperative placement of an inferior vena cava (IVC) filter may be necessary in patients with a history of thrombosis.






FIG 3 • Small glucagonomas (<2 cm) with no malignant features can be enucleated from the pancreas using cautery or an energy device to control bleeding. Intraoperative ultrasound should be used to avoid injury to the pancreatic duct.

Jul 24, 2016 | Posted by in GENERAL SURGERY | Comments Off on Surgery for Glucagonoma
Premium Wordpress Themes by UFO Themes
%d bloggers like this: